Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $30
Harrow Is Maintained at Buy by Craig-Hallum
Harrow Analyst Ratings
Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $30 From $26
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Harrow Rises 15% In Pre-market
Market-Moving News for June 20th
Express News | Harrow Shares Are Trading Higher After the Company Announced the Manufacture of the First of Three Commercial-scale Process Performance Qualification Batches of TRIESENCE 40 Mg/mL. Also the Company Announced That the Second and Third Required PPQ...
Harrow Hopes To Relaunch Triesence This Year
Harrow Announce Manufacture Of First Of Three Commercial-Scale Process Performance Qualification Batches Of Triesence For Visualization During Vitrectomy And Ocular Inflammatory Conditions, Harrow Says Second & Third Required PPQ Batches Are Scheduled
Express News | Harrow: IF Ppq Batches Meet Specifications, New Triesence Production Process to Be Deemed Complete, Allowing Co to Relaunch During 2024
Express News | Harrow Inc: Successful Manufacture of Triesence Ppq Batch
Express News | Harrow Provides Triesence® Relaunch Update
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29
Express News | Corrected-Melt Pharmaceuticals (Not 'harrow Inc'): Topline Readout Expected in Q4 2024
Express News | Harrow Inc: Topline Readout Expected in Q4 2024
Express News | Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating